TEVA PHARMACEUTICAL INDUSTRIES LTD

Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) operates as a biopharmaceutical company with over 120 years of history, combining a world-class generics business with innovative medicines and biosimilars. The company maintains its headquarters in Israel with significant operations across the United States, Europe, and more than 57 markets globally, employing approximately 34,000 people. The company website is www.tevapharm.com.

Teva operates through three primary business segments: United States, Europe, and International Markets, each managing a comprehensive product portfolio across generics, innovative medicines, biosimilars, and over-the-counter products. The United States segment positions Teva as a leading generic pharmaceutical company marketing more than 350 generic prescription products in various dosage forms, complemented by an innovative medicines portfolio focused on central nervous system disorders, respiratory conditions, and oncology. The Europe segment establishes Teva as a leading pharmaceutical company across the European Union, United Kingdom, and other European countries, with notable over-the-counter brands including SUDOCREM. The International Markets segment spans more than 35 countries, including highly regulated markets like Canada and Israel alongside branded generics-oriented markets.

Core innovative medicines include AUSTEDO for movement disorders, AJOVY for migraine prevention, UZEDY for schizophrenia and bipolar disorder, and COPAXONE for multiple sclerosis treatment. The biosimilars portfolio includes TRUXIMA, HERZUMA, RANIVISIO, SIMLANDI, SELARSDI, and EPYSQLI, with additional candidates in development. Teva manufactures approximately 66 billion tablets and capsules annually across 33 pharmaceutical plants in 21 countries, producing sterile injectables and specialized formulations.

The company pursues its "Pivot to Growth" strategy, focusing on expanding innovative and biosimilar medicines pipelines, sustaining a focused generic medicines business, and executing organizational transformation programs. Teva maintains vertical integration through active pharmaceutical ingredient manufacturing and operates Anda, a significant pharmaceutical distribution business in the United States. The company intends to divest its API business to concentrate resources on core growth engines and innovation initiatives.